KANEKA Corporation, the manufacturer of the evidence-based antioxidant Ubiquinol, has won the Annual Ingredient Cardiovascular Health Award at the Functional Foods for Wellness Summit (FFWS 2024) industry awards, held in Kuala Lumpur last week.
The FFWS Annual Ingredient Cardiovascular Award recognised Kaneka's contribution to supporting cardiovascular health with more than 45 years of research, 90-plus studies and over 80 patents that support the quality of its manufacturing.
Tsuyoshi Takakuwa, Head of Marketing and Sales at Kaneka, expressed his gratitude and excitement over the win.
"We are deeply honoured to receive this distinguished award from FFWS.
"It is a testament to our commitment to providing high-quality, evidence-based bioidentical Ubiquinol that supports cardiovascular health and overall wellbeing."
In Australia in 2020, there were an estimated 56,700 acute coronary events among people aged 25 and over, equivalent to around 155 events every day.
In 2021, coronary heart disease was the underlying cause of 17,300 deaths or 10% of all deaths, according to Australian Institute of Health and Welfare statistics.
Kaneka stated studies have shown that supplementing with ubiquinol has led to improvement in peripheral endothelial function in patients with heart failure with reduced ejection fraction and other cardiovascular issues.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Mar 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Mar 24
